Table 3.
Test characteristics of ZCS to exclude an abnormal PET
| Group | % ZCS | Sensitivity | Specificity | NPV | PPV | PLR | NLR |
|---|---|---|---|---|---|---|---|
| Abnormal PET (SSS ≥ 4) | |||||||
| Cohort | |||||||
| All patients | 25.9% | 96.8% | 32.2% | 97.4% | 27.7% | 1.43 | 0.10 |
| Male | 16.9% | 97.8% | 22.8% | 96.3% | 33.5% | 1.27 | 0.10 |
| Female | 36.7% | 94.0% | 41.2% | 98.0% | 18.6% | 1.60 | 0.15 |
| Age groups | |||||||
| < 40 | 88.9% | 100.0% | 90.9% | 100.0% | 20.0% | 11.00 | - |
| 40–49 | 61.2% | 92.3% | 65.6% | 99.0% | 18.2% | 2.68 | 0.12 |
| 50–59 | 40.0% | 93.4% | 45.8% | 97.6% | 22.4% | 1.72 | 0.14 |
| 60–69 | 20.5% | 97.2% | 25.6% | 97.1% | 26.3% | 1.31 | 0.11 |
| 70–79 | 14.3% | 96.6% | 18.2% | 94.0% | 28.5% | 1.18 | 0.19 |
| ≥ 80 | 6.2% | 100.0% | 9.9% | 100.0% | 40.1% | 1.11 | - |
| Male | |||||||
| < 40 | 80.8% | 100.0% | 84.0% | 100.0% | 20.0% | 6.25 | - |
| 40–49 | 52.4% | 90.9% | 57.6% | 98.1% | 20.4% | 2.15 | 0.16 |
| 50–59 | 28.2% | 93.5% | 34.0% | 95.4% | 26.3% | 1.42 | 0.19 |
| 60–69 | 9.1% | 99.3% | 12.7% | 97.7% | 32.5% | 1.14 | 0.06 |
| 70–79 | 3.7% | 98.3% | 4.8% | 83.3% | 37.7% | 1.03 | 0.34 |
| ≥ 80 | 2.5% | 100.0% | 4.9% | 100.0% | 49.6% | 1.05 | - |
| Female | |||||||
| < 50 | 80.2% | 100.0% | 82.1% | 100.0% | 11.8% | 5.60 | - |
| 50–59 | 58.0% | 92.9% | 61.0% | 99.3% | 12.4% | 2.38 | 0.12 |
| 60–69 | 35.0% | 90.2% | 38.5% | 96.9% | 15.4% | 1.47 | 0.25 |
| 70–79 | 23.9% | 92.6% | 27.1% | 95.5% | 18.1% | 1.27 | 0.27 |
| ≥ 80 | 9.3% | 100.0% | 13.0% | 100.0% | 31.5% | 1.15 | - |
Table displays the test characteristics of ZCS for predicting abnormal PET (SSS ≥ 4). %ZCS denotes the proportion of patients with ZCS in each group. Due to low number of cases, the first two age groups were taken together in women
NPV, negative predictive values, PPV, positive predictive value, PLR, positive likelihood ration, NLR, negative likely hood ratio, ZCS, zero calcium score